New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L04 IMMUNOSUPPRESSANTS
Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
L04A IMMUNOSUPPRESSANTS
This group comprises immunosuppressants excl. corticosteroids.
| The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. |
L04AF Janus-associated kinase (JAK) inhibitors
Tyrosine kinase 2 (TYK2) inhibitors are classified in this group.
| The DDD for tofacitinib is based on the treatment of rheumatoid arthritis. |
| ATC code | Name | DDD | U | Adm.R | Note |
| L04AF01 | tofacitinib | 10 | mg | O | |
| L04AF02 | baricitinib | 3 | mg | O | |
| L04AF03 | upadacitinib | 15 | mg | O | |
| L04AF04 | filgotinib | 0.2 | g | O | |
| L04AF05 | itacitinib | ||||
| L04AF06 | peficitinib | ||||
| L04AF07 | deucravacitinib | ||||
| L04AF08 | ritlecitinib |
Last updated: 2024-01-26